Comparison of Two Symptom Checkers (Ada and Symptoma) in the Emergency Department: Randomized, Crossover, Head-to-Head, Double-Blinded Study.


Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
20 Aug 2024
Historique:
received: 19 01 2024
accepted: 21 06 2024
revised: 19 03 2024
medline: 20 8 2024
pubmed: 20 8 2024
entrez: 20 8 2024
Statut: epublish

Résumé

Emergency departments (EDs) are frequently overcrowded and increasingly used by nonurgent patients. Symptom checkers (SCs) offer on-demand access to disease suggestions and recommended actions, potentially improving overall patient flow. Contrary to the increasing use of SCs, there is a lack of supporting evidence based on direct patient use. This study aimed to compare the diagnostic accuracy, safety, usability, and acceptance of 2 SCs, Ada and Symptoma. A randomized, crossover, head-to-head, double-blinded study including consecutive adult patients presenting to the ED at University Hospital Erlangen. Patients completed both SCs, Ada and Symptoma. The primary outcome was the diagnostic accuracy of SCs. In total, 6 blinded independent expert raters classified diagnostic concordance of SC suggestions with the final discharge diagnosis as (1) identical, (2) plausible, or (3) diagnostically different. SC suggestions per patient were additionally classified as safe or potentially life-threatening, and the concordance of Ada's and physician-based triage category was assessed. Secondary outcomes were SC usability (5-point Likert-scale: 1=very easy to use to 5=very difficult to use) and SC acceptance net promoter score (NPS). A total of 450 patients completed the study between April and November 2021. The most common chief complaint was chest pain (160/437, 37%). The identical diagnosis was ranked first (or within the top 5 diagnoses) by Ada and Symptoma in 14% (59/437; 27%, 117/437) and 4% (16/437; 13%, 55/437) of patients, respectively. An identical or plausible diagnosis was ranked first (or within the top 5 diagnoses) by Ada and Symptoma in 58% (253/437; 75%, 329/437) and 38% (164/437; 64%, 281/437) of patients, respectively. Ada and Symptoma did not suggest potentially life-threatening diagnoses in 13% (56/437) and 14% (61/437) of patients, respectively. Ada correctly triaged, undertriaged, and overtriaged 34% (149/437), 13% (58/437), and 53% (230/437) of patients, respectively. A total of 88% (385/437) and 78% (342/437) of participants rated Ada and Symptoma as very easy or easy to use, respectively. Ada's NPS was -34 (55% [239/437] detractors; 21% [93/437] promoters) and Symptoma's NPS was -47 (63% [275/437] detractors and 16% [70/437]) promoters. Ada demonstrated a higher diagnostic accuracy than Symptoma, and substantially more patients would recommend Ada and assessed Ada as easy to use. The high number of unrecognized potentially life-threatening diagnoses by both SCs and inappropriate triage advice by Ada was alarming. Overall, the trustworthiness of SC recommendations appears questionable. SC authorization should necessitate rigorous clinical evaluation studies to prevent misdiagnoses, fatal triage advice, and misuse of scarce medical resources. German Register of Clinical Trials DRKS00024830; https://drks.de/search/en/trial/DRKS00024830.

Sections du résumé

BACKGROUND BACKGROUND
Emergency departments (EDs) are frequently overcrowded and increasingly used by nonurgent patients. Symptom checkers (SCs) offer on-demand access to disease suggestions and recommended actions, potentially improving overall patient flow. Contrary to the increasing use of SCs, there is a lack of supporting evidence based on direct patient use.
OBJECTIVE OBJECTIVE
This study aimed to compare the diagnostic accuracy, safety, usability, and acceptance of 2 SCs, Ada and Symptoma.
METHODS METHODS
A randomized, crossover, head-to-head, double-blinded study including consecutive adult patients presenting to the ED at University Hospital Erlangen. Patients completed both SCs, Ada and Symptoma. The primary outcome was the diagnostic accuracy of SCs. In total, 6 blinded independent expert raters classified diagnostic concordance of SC suggestions with the final discharge diagnosis as (1) identical, (2) plausible, or (3) diagnostically different. SC suggestions per patient were additionally classified as safe or potentially life-threatening, and the concordance of Ada's and physician-based triage category was assessed. Secondary outcomes were SC usability (5-point Likert-scale: 1=very easy to use to 5=very difficult to use) and SC acceptance net promoter score (NPS).
RESULTS RESULTS
A total of 450 patients completed the study between April and November 2021. The most common chief complaint was chest pain (160/437, 37%). The identical diagnosis was ranked first (or within the top 5 diagnoses) by Ada and Symptoma in 14% (59/437; 27%, 117/437) and 4% (16/437; 13%, 55/437) of patients, respectively. An identical or plausible diagnosis was ranked first (or within the top 5 diagnoses) by Ada and Symptoma in 58% (253/437; 75%, 329/437) and 38% (164/437; 64%, 281/437) of patients, respectively. Ada and Symptoma did not suggest potentially life-threatening diagnoses in 13% (56/437) and 14% (61/437) of patients, respectively. Ada correctly triaged, undertriaged, and overtriaged 34% (149/437), 13% (58/437), and 53% (230/437) of patients, respectively. A total of 88% (385/437) and 78% (342/437) of participants rated Ada and Symptoma as very easy or easy to use, respectively. Ada's NPS was -34 (55% [239/437] detractors; 21% [93/437] promoters) and Symptoma's NPS was -47 (63% [275/437] detractors and 16% [70/437]) promoters.
CONCLUSIONS CONCLUSIONS
Ada demonstrated a higher diagnostic accuracy than Symptoma, and substantially more patients would recommend Ada and assessed Ada as easy to use. The high number of unrecognized potentially life-threatening diagnoses by both SCs and inappropriate triage advice by Ada was alarming. Overall, the trustworthiness of SC recommendations appears questionable. SC authorization should necessitate rigorous clinical evaluation studies to prevent misdiagnoses, fatal triage advice, and misuse of scarce medical resources.
TRIAL REGISTRATION BACKGROUND
German Register of Clinical Trials DRKS00024830; https://drks.de/search/en/trial/DRKS00024830.

Identifiants

pubmed: 39163594
pii: v26i1e56514
doi: 10.2196/56514
doi:

Types de publication

Journal Article Randomized Controlled Trial Comparative Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e56514

Informations de copyright

©Johannes Knitza, Ragip Hasanaj, Jonathan Beyer, Franziska Ganzer, Anna Slagman, Myrto Bolanaki, Hendrik Napierala, Malte L Schmieding, Nizam Al-Zaher, Till Orlemann, Felix Muehlensiepen, Julia Greenfield, Nicolas Vuillerme, Sebastian Kuhn, Georg Schett, Stephan Achenbach, Katharina Dechant. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 20.08.2024.

Auteurs

Johannes Knitza (J)

Institute for Digital Medicine, University Hospital Giessen, Philipps University, Marburg, Germany.
Department of Internal Medicine 3, Friedrich-Alexander University Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Germany.
Deutsches Zentrum für Immuntherapie, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Université Grenoble Alpes, Grenoble, France.

Ragip Hasanaj (R)

Department of Cardiology, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

Jonathan Beyer (J)

Department of Cardiology, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

Franziska Ganzer (F)

Department of Cardiology, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

Anna Slagman (A)

Emergency and Acute Medicine and Health Services Research in Emergency Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Myrto Bolanaki (M)

Emergency and Acute Medicine and Health Services Research in Emergency Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Hendrik Napierala (H)

Institute of General Practice and Family Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Malte L Schmieding (ML)

Institute of Medical Informatics, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Nizam Al-Zaher (N)

Department of Cardiology, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Department of Medicine 1, Friedrich-Alexander University Hospital Erlangen, University Erlangen-Nuremberg, Erlangen, Germany.

Till Orlemann (T)

Deutsches Zentrum für Immuntherapie, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Department of Medicine 1, Friedrich-Alexander University Hospital Erlangen, University Erlangen-Nuremberg, Erlangen, Germany.

Felix Muehlensiepen (F)

Université Grenoble Alpes, Grenoble, France.
Centre for Health Services Research Brandenburg, Brandenburg Medical School, Rüdersdorf, Germany.

Julia Greenfield (J)

Institute for Digital Medicine, University Hospital Giessen, Philipps University, Marburg, Germany.

Nicolas Vuillerme (N)

Université Grenoble Alpes, Grenoble, France.
Institut Universitaire de France, Paris, France.
Orange Labs & Université Grenoble Alpes, Grenoble, France.

Sebastian Kuhn (S)

Institute for Digital Medicine, University Hospital Giessen, Philipps University, Marburg, Germany.

Georg Schett (G)

Department of Internal Medicine 3, Friedrich-Alexander University Erlangen-Nürnberg, Universitätsklinikum Erlangen, Erlangen, Germany.
Deutsches Zentrum für Immuntherapie, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.

Stephan Achenbach (S)

Department of Cardiology, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

Katharina Dechant (K)

Department of Cardiology, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH